MSCA-PF projects involving clinical trials
Dear Research Executive Agency,
Under the right of access to documents in the EU treaties, as developed in Regulation 1049/2001, I am requesting documents which contain the following information:
The number of MSCA-PF project applications that involved a Clinical Trial of an Investigative Medicinal Product (CTIMP) and received funding, broken down annually by year of application for funding, for the years: 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023 and 2024.
(MSCA-PF applicants have to tick a box indicating whether their proposal contains plans for a CTIMP, so these data should be easy to retrieve. In case these data are not readily available for earlier years, please contact me for clarification before launching an in-depth search.)
My postal address is Am Buechel 53b, 53173 Bonn, Germany.
I would prefer to receive the requested figures via this platform, rather than by post.
Yours faithfully,
Till Bruckner
Link: [1]File-List
Link: [2]themeData
Link: [3]colorSchemeMapping
[4]AoR- Request for Access to REA Documents for MSCA-PF projects
applications involving Clinical Trial of an Investigative Medicinal
Product - Ares(2025)4653018 (Please use this link only if you are an Ares
user – Svp, utilisez ce lien exclusivement si vous êtes un(e) utilisateur
d’Ares)
Dear Mr Bruckner,
We refer to your Access to Documents request submitted to the European
Research Executive Agency (REA) on 06/06/2025 via the website AskTheEU.org
and registered on 11/06/2025 under reference number Ares(2025)4651225.
Please note that you request was just found today in the spam folder of
the REA access to documents mailbox.
In accordance with Regulation (EC) No 1049/2001 regarding public access to
European Parliament, Council and Commission documents, your application
will be handled within 15 working days. The time limit will expire on
02/07/2025. In case this time limit needs to be extended, you will be
informed in due course.
Kindly note that the AsktheEU.org website is a private third-party website
which has no link with any institution of the European Union. Therefore,
the European Commission or REA cannot be held accountable for any
technical issues or problems linked to the use of this system.
Please also note that the private third party running the AsktheEU.org
website is responsible and accountable for the processing of your personal
data via that website, and not the European Commission or REA. For further
information on your rights, please refer to the third party’s privacy
policy.
We understand that the third party running that website usually publishes
the content of applicants’ correspondence with the European Commission or
REA on that website. This includes the personal data that you may have
communicated to the European Commission or REA (e.g. your private postal
address). Similarly, the third party publishes on that website any reply
that REA will send to the email address of the applicants generated by the
AsktheEU.org website.
If you do not wish your correspondence with REA to be published on the
AsktheEU.org website, you can provide us with an alternative, private
e-mail address for further correspondence. In that case, REA will send all
future electronic correspondence addressed to you only to that private
address.
Yours faithfully,
REA ACCESS TO DOCUMENTS
For information related to the processing of your personal data by REA,
you may consult the relevant [5]Data Protection Notice
Link: [1]File-List
Link: [2]Edit-Time-Data
Link: [3]themeData
Link: [4]colorSchemeMapping
[5]Request for clarification- request for Access to REA Documents for
MSCA-PF projects applications involving Clinical Trial of an Investigative
Medicinal Product - Ares(2025)5062218 (Please use this link only if you
are an Ares user – Svp, utilisez ce lien exclusivement si vous êtes un(e)
utilisateur d’Ares)
Dear Mr Bruckner,
We refer to your Access to Documents request submitted to the European
Research Executive Agency (REA) on 06/06/2025 via the website AskTheEU.org
and registered on 11/06/2025 under reference number Ares(2025)4651225.
Concerning the scope of your request, we have noted your interest in
receiving the total number of MSCA-PF project applications that involved
a Clinical Trial of an Investigative Medicinal Product (CTIMP) and
received funding, broken down annually by year of application for funding,
for the years: 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023
and 2024.
You stated in your request that MSCA-PF applicants have to tick a box
indicating whether their proposal contains plans for a CTIMP.
We have performed a search and while for the proposals falling under
Horizon Europe Programme (2021-2027) there is the following box with the
two sub-questions that the applicants have to tick in the proposal part A
(see the example just below):
we are not sure whether this is exactly the type of information you are
looking for. Therefore, in line with Article 6(2) of Regulation (EC) No
1049/2001, we invite you to clarify that.
Are you interested in the statistics with regards to all the three points
mentioned above, one , two of those or none at all – please specify.
As regards the data for earlier years, it is to be noted that for the
proposals falling under Horizon2020 Programme (2014-2020) this option was
not listed in the proposal part A.
In this context, we also invite you to consult the EU portal
named [6]Clinical Trials Information System (CTIS), which was launched on
31/01/2022.
In the meantime, we remain available to assist you in the precise
definition of your request.
The 15 working days to reply to your request will be put on hold and will
start running again only when you reply to this message. If you do not
reply within 7 working days, we will close this case in line with our
detailed rules for the application of Regulation (EC) No 1049/2001.
Kind regards,
REA Access to Documents
From: REA ACCESS DOCUMENTS <[email address]>
Sent: Wednesday, June 11, 2025 12:43 PM
To: Till Bruckner <[FOI #15983 email]>
Cc: REA ACCESS DOCUMENTS <[REA request email]>
Subject: AoR- Request for Access to REA Documents for MSCA-PF projects
applications involving Clinical Trial of an Investigative Medicinal
Product - Ares(2025)4653018
[7]AoR- Request for Access to REA Documents for MSCA-PF projects
applications involving Clinical Trial of an Investigative Medicinal
Product - Ares(2025)4653018 (Please use this link only if you are an Ares
user – Svp, utilisez ce lien exclusivement si vous êtes un(e) utilisateur
d’Ares)
Dear Mr Bruckner,
We refer to your Access to Documents request submitted to the European
Research Executive Agency (REA) on 06/06/2025 via the website AskTheEU.org
and registered on 11/06/2025 under reference number Ares(2025)4651225.
Please note that you request was just found today in the spam folder of
the REA access to documents mailbox.
In accordance with Regulation (EC) No 1049/2001 regarding public access to
European Parliament, Council and Commission documents, your application
will be handled within 15 working days. The time limit will expire on
02/07/2025. In case this time limit needs to be extended, you will be
informed in due course.
Kindly note that the AsktheEU.org website is a private third-party website
which has no link with any institution of the European Union. Therefore,
the European Commission or REA cannot be held accountable for any
technical issues or problems linked to the use of this system.
Please also note that the private third party running the AsktheEU.org
website is responsible and accountable for the processing of your personal
data via that website, and not the European Commission or REA. For further
information on your rights, please refer to the third party’s privacy
policy.
We understand that the third party running that website usually publishes
the content of applicants’ correspondence with the European Commission or
REA on that website. This includes the personal data that you may have
communicated to the European Commission or REA (e.g. your private postal
address). Similarly, the third party publishes on that website any reply
that REA will send to the email address of the applicants generated by the
AsktheEU.org website.
If you do not wish your correspondence with REA to be published on the
AsktheEU.org website, you can provide us with an alternative, private
e-mail address for further correspondence. In that case, REA will send all
future electronic correspondence addressed to you only to that private
address.
Yours faithfully,
REA ACCESS TO DOCUMENTS
For information related to the processing of your personal data by REA,
you may consult the relevant [8]Data Protection Notice
Dear Mr Bruckner,
We have noticed that the linked image cannot be displayed, therefore we
are sending you the image in the pdf format.
Apologies for the inconvenience.
Kind regards,
REA Access to Documents
From: REA ACCESS DOCUMENTS <[email address]>
Sent: Wednesday, June 25, 2025 1:34 PM
To: Till Bruckner <[FOI #15983 email]>
Cc: REA ACCESS DOCUMENTS <[REA request email]>
Subject: Request for clarification- request for Access to REA Documents
for MSCA-PF projects applications involving Clinical Trial of an
Investigative Medicinal Product - Ares(2025)5062218
[1]Request for clarification- request for Access to REA Documents for
MSCA-PF projects applications involving Clinical Trial of an Investigative
Medicinal Product - Ares(2025)5062218 (Please use this link only if you
are an Ares user – Svp, utilisez ce lien exclusivement si vous êtes un(e)
utilisateur d’Ares)
Dear Mr Bruckner,
We refer to your Access to Documents request submitted to the European
Research Executive Agency (REA) on 06/06/2025 via the website AskTheEU.org
and registered on 11/06/2025 under reference number Ares(2025)4651225.
Concerning the scope of your request, we have noted your interest in
receiving the total number of MSCA-PF project applications that involved
a Clinical Trial of an Investigative Medicinal Product (CTIMP) and
received funding, broken down annually by year of application for funding,
for the years: 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023
and 2024.
You stated in your request that MSCA-PF applicants have to tick a box
indicating whether their proposal contains plans for a CTIMP.
We have performed a search and while for the proposals falling under
Horizon Europe Programme (2021-2027) there is the following box with the
two sub-questions that the applicants have to tick in the proposal part A
(see the example just below):
we are not sure whether this is exactly the type of information you are
looking for. Therefore, in line with Article 6(2) of Regulation (EC) No
1049/2001, we invite you to clarify that.
Are you interested in the statistics with regards to all the three points
mentioned above, one , two of those or none at all – please specify.
As regards the data for earlier years, it is to be noted that for the
proposals falling under Horizon2020 Programme (2014-2020) this option was
not listed in the proposal part A.
In this context, we also invite you to consult the EU portal
named [2]Clinical Trials Information System (CTIS), which was launched on
31/01/2022.
In the meantime, we remain available to assist you in the precise
definition of your request.
The 15 working days to reply to your request will be put on hold and will
start running again only when you reply to this message. If you do not
reply within 7 working days, we will close this case in line with our
detailed rules for the application of Regulation (EC) No 1049/2001.
Kind regards,
REA Access to Documents
From: REA ACCESS DOCUMENTS <[3][email address]>
Sent: Wednesday, June 11, 2025 12:43 PM
To: Till Bruckner <[4][FOI #15983 email]>
Cc: REA ACCESS DOCUMENTS <[5][REA request email]>
Subject: AoR- Request for Access to REA Documents for MSCA-PF projects
applications involving Clinical Trial of an Investigative Medicinal
Product - Ares(2025)4653018
[6]AoR- Request for Access to REA Documents for MSCA-PF projects
applications involving Clinical Trial of an Investigative Medicinal
Product - Ares(2025)4653018 (Please use this link only if you are an Ares
user – Svp, utilisez ce lien exclusivement si vous êtes un(e) utilisateur
d’Ares)
Dear Mr Bruckner,
We refer to your Access to Documents request submitted to the European
Research Executive Agency (REA) on 06/06/2025 via the website AskTheEU.org
and registered on 11/06/2025 under reference number Ares(2025)4651225.
Please note that you request was just found today in the spam folder of
the REA access to documents mailbox.
In accordance with Regulation (EC) No 1049/2001 regarding public access to
European Parliament, Council and Commission documents, your application
will be handled within 15 working days. The time limit will expire on
02/07/2025. In case this time limit needs to be extended, you will be
informed in due course.
Kindly note that the AsktheEU.org website is a private third-party website
which has no link with any institution of the European Union. Therefore,
the European Commission or REA cannot be held accountable for any
technical issues or problems linked to the use of this system.
Please also note that the private third party running the AsktheEU.org
website is responsible and accountable for the processing of your personal
data via that website, and not the European Commission or REA. For further
information on your rights, please refer to the third party’s privacy
policy.
We understand that the third party running that website usually publishes
the content of applicants’ correspondence with the European Commission or
REA on that website. This includes the personal data that you may have
communicated to the European Commission or REA (e.g. your private postal
address). Similarly, the third party publishes on that website any reply
that REA will send to the email address of the applicants generated by the
AsktheEU.org website.
If you do not wish your correspondence with REA to be published on the
AsktheEU.org website, you can provide us with an alternative, private
e-mail address for further correspondence. In that case, REA will send all
future electronic correspondence addressed to you only to that private
address.
Yours faithfully,
REA ACCESS TO DOCUMENTS
For information related to the processing of your personal data by REA,
you may consult the relevant [7]Data Protection Notice
Dear REA ACCESS DOCUMENTS,
Thank you for your response. I amend my request as follows:
The number of MSCA-PF project applications that involved conducting a "clinical study" and received funding, broken down annually by year of application for funding, for the years: 2021, 2022, 2023 and 2024.
Provision of the relevant numbers disaggregated for each of those four years (rather than any original documents containing those numbers) would be sufficient.
Yours sincerely,
Till Bruckner
[1]RE: Request for clarification- request for Access to REA Documents for
MSCA-PF projects applications involving Clinical Trial of an Investigative
Medicinal Product - Ares(2025)5071086 (Please use this link only if you
are an Ares user – Svp, utilisez ce lien exclusivement si vous êtes un(e)
utilisateur d’Ares)
Dear Mr Bruckner,
Many thanks for your quick clarification.
Kind regards,
REA Access to Documents
Dear Mr. Bruckner,
Please find hereby attached and registered under the reference no. Ares(2025)5302688, REA reply to your request for access to REA documents for MSCA-PF projects applications involving Clinical Trial of an Investigative Medicinal Product, requalified to access to information.
Kind regards,
REA ACCESS TO DOCUMENTS
Dear REA ACCESS DOCUMENTS,
Thank you very much for your rapid and comprehensive response.
Yours sincerely,
Till Bruckner